Cargando…
Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer.
PS2, an oestrogen-inducible protein, was measured in the cytosol of 230 primary tumours from patients who were subjected to first-line tamoxifen therapy for advanced disease without prior adjuvant therapy with tamoxifen. PS2 correlated positively with oestrogen receptor (ER, P < 0.01) and progest...
Autores principales: | Foekens, J. A., Portengen, H., Look, M. P., van Putten, W. L., Thirion, B., Bontenbal, M., Klijn, J. G. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1994
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033706/ https://www.ncbi.nlm.nih.gov/pubmed/7981080 |
Ejemplares similares
-
Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer
por: Foekens, J A, et al.
Publicado: (1999) -
Feasibility, endocrine and anti-tumour effects of a triple endocrine therapy with tamoxifen, a somatostatin analogue and an antiprolactin in post-menopausal metastatic breast cancer: a randomized study with long-term follow-up.
por: Bontenbal, M., et al.
Publicado: (1998) -
Elevated expression of polymorphonuclear leukocyte elastase in breast cancer tissue is associated with tamoxifen failure in patients with advanced disease
por: Foekens, J A, et al.
Publicado: (2003) -
Phosphoserine aminotransferase 1 is associated to poor outcome on tamoxifen therapy in recurrent breast cancer
por: De Marchi, Tommaso, et al.
Publicado: (2017) -
Prognostic value of cytosolic tyrosine kinase activity in 249 node-positive breast cancer patients.
por: Romain, S., et al.
Publicado: (1994)